Why Is Sandostatin So Hard to Find? [Explained for 2026]

You called your pharmacy. You heard those dreaded words: "We don't have it in stock." If you rely on Sandostatin for acromegaly, carcinoid syndrome, or a VIPoma, not being able to fill your prescription isn't just inconvenient — it can seriously affect your health.

The hard truth is that Sandostatin — and its generic, octreotide — has been one of the most persistently difficult specialty medications to reliably fill over the past several years. In 2026, supply has improved but remains inconsistent. Here's exactly why that is, and what you can do about it.

What Is Sandostatin?

Sandostatin is a brand name for octreotide acetate, a synthetic version of somatostatin — a hormone your body produces naturally to regulate the secretion of other hormones. Made by Novartis, Sandostatin comes in two main forms: an immediate-release injection you or a nurse administers several times a day, and Sandostatin LAR Depot, a long-acting injection given once every four weeks at a clinic or specialty pharmacy.

It is FDA-approved for three conditions: acromegaly (excess growth hormone), carcinoid syndrome (severe flushing and diarrhea caused by metastatic carcinoid tumors), and VIPomas (profuse watery diarrhea from vasoactive intestinal peptide-secreting tumors). It's also used off-label for neuroendocrine tumors (NETs), esophageal variceal bleeding, and dumping syndrome, among other conditions.

Why Is Sandostatin So Hard to Find in 2026?

There isn't one single reason — it's a convergence of factors that have created ongoing supply instability. Here are the main ones:

1. The LAR Formulation Is Extraordinarily Difficult to Manufacture

Sandostatin LAR Depot — the once-monthly injection that most long-term patients rely on — uses a microsphere technology. The drug is encapsulated inside tiny biodegradable polymer spheres that release octreotide slowly over four weeks. This process requires specialized equipment, rigorous quality controls, and manufacturing expertise that very few pharmaceutical facilities in the world possess.

When something goes wrong in production — a contamination event, a quality deviation, a regulatory finding — it can take months to correct. Unlike a basic tablet or capsule, you can't quickly shift LAR manufacturing to another facility.

2. Very Few Manufacturers Make Sandostatin LAR

For years, Novartis was essentially the only manufacturer of the long-acting depot formulation. The first generic LAR equivalent — made by Teva — wasn't FDA-approved until October 2024. That's a remarkably narrow supplier base for a medication that thousands of patients depend on monthly. Even with Teva's entry, both Novartis and Teva have experienced supply constraints into 2025 and 2026.

3. A Recent History of Shortage Events

The shortage history has been multi-year:

• 2020–2021: Initial supply disruptions for generic immediate-release octreotide injection. Sun Pharma discontinued the Bynfezia Pen delivery device.
• 2022–2023: Sandostatin LAR Depot experienced intermittent availability issues.
• October 2024: FDA approved Teva's generic Octreotide Acetate for Injectable Suspension (first generic LAR competitor).
• 2025: Teva's generic LAR 20 mg kit went on backorder through late 2025. Sagent reported manufacturing delays for immediate-release injections.
• 2026 (current): Supply is improving but remains inconsistent across formulations and geographies.

4. Sandostatin LAR Is a Specialty Medication Distributed Through Special Channels

Unlike medications you pick up at any corner pharmacy, Sandostatin LAR Depot is dispensed only through specialty pharmacies. These facilities require cold-chain storage, special handling, and clinical coordination. Your neighborhood CVS or Walgreens almost certainly does not stock it. When supply tightens, patients in certain regions may be completely cut off, even when stock exists elsewhere.

What Can You Do Right Now?

Don't panic — there are concrete steps you can take:

1. Use medfinder to locate pharmacies with Sandostatin in stock near you. Instead of calling pharmacy after pharmacy, medfinder contacts pharmacies on your behalf to find which ones can fill your prescription.
2. Ask your doctor about bridging with immediate-release octreotide. When the LAR formulation is unavailable, patients can be bridged with subcutaneous immediate-release octreotide at 100–200 mcg two to three times daily. It's more widely available from multiple manufacturers including Avet, Fresenius Kabi, Hikma, and Sagent.
3. Ask about generic octreotide LAR. Teva's generic LAR is bioequivalent to Sandostatin LAR Depot. If your pharmacy can't source the brand, they may be able to obtain the generic through different distribution channels.
4. Ask about alternatives if Sandostatin is unavailable in any formulation. Lanreotide (Somatuline Depot) is manufactured by Ipsen and has an independent supply chain, making it a practical backup for most patients with acromegaly, carcinoid syndrome, or NETs.
5. Contact Novartis Patient Support (1-800-277-2254). They may be able to help you locate a dispensing pharmacy or access emergency supply.

Is the Sandostatin Shortage Getting Better?

The overall trajectory is positive. The entry of Teva's generic LAR in October 2024 introduced competition and a new supply source. Additional manufacturers are expected to enter the LAR market over the next few years. However, given the fundamental complexity of microsphere manufacturing, supply vulnerability will persist until a broader manufacturer base exists.

In the meantime, your best tools are proactive communication with your prescriber, knowing your alternatives, and using patient-focused services to locate available stock.

The Bottom Line

Sandostatin is hard to find because it combines a complex manufacturing process, a historically narrow supplier base, and a specialty-only distribution channel. Supply is slowly improving in 2026 — but inconsistencies remain. The best things you can do are stay informed, maintain communication with your care team, and use tools like medfinder to actively locate pharmacies with stock. Read our guide on how to find Sandostatin in stock near you for more specific strategies.